MGI Pharma MOGN
-
New Data for Competing Cancer Drugs
… blood cancer indications a tougher challenge. Japanese pharmaceutical firm Eisai announced that it plans to acquire MGI Pharma MOGN for $3.9 billion in cash, putting a high-powered firm behind MGI's Dacogen, which is a key competitor to …
-
MGI Pharma Agrees to Be Acquired
MGI Pharma MOGN agreed Monday to be acquired by Japan's Eisai for $41 cash per share, which represents a 40% premium to MGI's stock price …
-
Celgene to Acquire Pharmion
… the weak patent protection on this product, we think this will open the door to generic competition. Sales of MGI Pharma 's MOGN competing drug Dacogen, which appears highly similar to Vidaza, are also growing rapidly. In addition, Celgene …
-
Maintaining MGI Pharma's Fair Value
We're maintaining our fair value estimate for MGI Pharma MOGN , as Wednesday's poor first-quarter results were on par with our expectations. The conversion of competing drug Zofran to …
-
MGI Dodges Gliadel Bullet
MGI Pharma MOGN dodged a small bullet Monday when competitor NeoPharm's NEOL drug candidate for brain tumors failed to show significantly better …
-
MGI's Saforis Delayed
MGI Pharma MOGN received an approvable letter instead of approval for Saforis from the Food and Drug Administration on Thursday; the agency is …
-
A Look at Recent Fair Value Changes
… in late July. Notable Fair Value Estimate Downgrades Company New Fair Value Old Fair Value % Change Date of Change MGI Pharma MOGN $16 $27 -40.7% 8-01-06 Valassis VCI $22 $27 -18.5% 8-02-06 New York Times NYT $33 $40 -17 …
-
Lowering MGI's Fair Value Estimate
We're reducing MGI Pharma 's MOGN fair value estimate to $16 per share from $27 to reflect a number of negative items unearthed during the firm's recent disappointing …
-
MGI Lowers 2006 Guidance
We're placing MGI Pharma 's MOGN fair value estimate under review following Wednesday's disappointing second-quarter earnings and lower 2006 guidance. Management …
-
NeoPharm Awaits Final IL13 Results
… company with more than 20 years of related experience. Interestingly, he most recently held a similar position at MGI Pharma MOGN , the company that markets IL13's potential competitor, Gliadel.